ALNYLAM PHARMACEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Feb 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 2. PROPERTIES
Our operations are based primarily in Cambridge, Massachusetts; Zug, Switzerland; Maidenhead, United Kingdom; Amsterdam, Netherlands; and Tokyo, Japan. A description of certain of the facilities we lease or own as of January 31, 2026 is included in the table below.
| Location | Primary Use | ApproximateSquare Footage | LeaseExpiration Date | Renewal Option |
|---|---|---|---|---|
| 675 West Kendall Street Henri A. Termeer Square Cambridge, Massachusetts | Corporate headquarters and primary research facility | 295,000 | January 2034 | Two five-year terms |
| 300 Third StreetCambridge, Massachusetts | Office space and additional research facility | 129,000 | January 2034 | Two five-year terms |
| 101 Main StreetCambridge, Massachusetts | Office space | 23,350 | June 2029 | Two two-year terms |
| 20 Commerce WayNorton, Massachusetts | GMP manufacturing | 200,000 | Owned | Owned |
| 665 Concord AvenueCambridge, Massachusetts | GMP manufacturing | 15,000 | September 2027 | One five-year term |
| Grafenauweg 2 & 46300 Zug, Switzerland | International headquarters | 15,800 | May 2029 | One five-year term |
| 27 Market Street, MaidenheadBerkshire, United Kingdom | Office space | 15,600 | October 2035 | One five-year term |
| Wisdom Cross Tower Antonio Vivaldistraat 150Amsterdam, Netherlands | Office space | 12,500 | April 2030 | One five-year term |
| Pacific Century Place1-Chome-11-1 Marunouchi Chiyoda-ku Tokyo, Japan | Office space | 12,700 | May 2028 | None |
In addition to the locations above, we also occupy small offices in multiple locations in and outside of the U.S. to support our operations and growth.
In the future, we may lease, operate, purchase or construct additional facilities in which to conduct expanded research, development and manufacturing activities and support future commercial operations. We believe that the total space available to us under our current leases will meet our needs for the foreseeable future and that additional space would be available to us on commercially reasonable terms if required.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.